Investigational antiviral drugs for the treatment of COVID-19 patients

Beheshtirouy, Samineh; Khani, Elnaz; Khiali, Sajad; Entezari‐Maleki, Taher

doi:10.1007/s00705-022-05368-z

Cited by 10 publications

(7 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[37] It has been demonstrated that ritonavir improves the efficacy of several ARVs. For instance, in HIVinfected individuals who had received therapy in the past as well as those who had never had it, the combination of lopinavir and ritonavir effectively decreased viral load and improved immunological markers [38,39]. Ritonavir is being explored in conjunction with antineoplastic medicines to treat cancer due to its mechanisms of action.…”

Section: Covid-19 Therapeutic Implications Of Ritonavirmentioning

confidence: 99%

Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19?

2024

IJFMR

View full text Add to dashboard Cite

Nirmatrelvir Ritonavir 3-c like protease COVID-19 SARS-COV-2Despite the need for innovative, efficient treatment for the Covid Pandemic, there is currently no curative regimen available, leaving patients to rely on supportive and general treatments. The 3C like-protease (3CLpro) and the main protease (Mpro), two SARS-COV-2 proteins, have been identified as potential targets for antiviral medications. The Mpro might be viable therapeutic target since it plays a significant role in both the pathogenesis of the virus and processing. Nirmatrelvir, an antiviral medication, prevents SARS-CoV-2 from reproducing by blocking Mpro. Another HIV protease inhibitor, ritonavir, was coupled with nirmatrelvir to develop. Ritonavir inhibits the cytochrome P450 3A metabolizing enzyme, extending the half-life of nirmatrelvir and serving as pharmacological enhancer. Despite major modification of the SARS-COV-2 viral genome, nirmatrelvir still has strong antiviral effectiveness against contemporary coronavirus strains. However, there are still a number of open issues. The effectiveness of nirmatrelvir and ritonavir in treating SARS-COV-2 infection, as well as their safety and potential adverse effects are discussed in this review of literature.

show abstract

Section: Covid-19 Therapeutic Implications Of Ritonavirmentioning

confidence: 99%

Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19?

2024

IJFMR

View full text Add to dashboard Cite

show abstract

“…The ongoing threat of viral infections, such as influenza virus [154], coronavirus disease 2019 (COVID-19) virus [155], and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus [156], underscores the importance of effective antiviral therapies in preventing disease spread, mitigating viral damage, and facilitating patient recovery. Antiviral drugs not only help control outbreaks and improve treatment outcomes but also minimize the risk of viral mutations and drug resistance.…”

Section: Antiviral Activitymentioning

confidence: 99%

Research Progress on Sesquiterpene Compounds from Artabotrys Plants of Annonaceae

Sun,

Xin,

et al. 2024

Molecules

View full text Add to dashboard Cite

Artabotrys, a pivotal genus within the Annonaceae family, is renowned for its extensive biological significance and medicinal potential. The genus’s sesquiterpene compounds have attracted considerable interest from the scientific community due to their structural complexity and diverse biological activities. These compounds exhibit a range of biological activities, including antimalarial, antibacterial, anti-inflammatory analgesic, and anti-tumor properties, positioning them as promising candidates for medical applications. This review aims to summarize the current knowledge on the variety, species, and structural characteristics of sesquiterpene compounds isolated from Artabotrys plants. Furthermore, it delves into their pharmacological activities and underlying mechanisms, offering a comprehensive foundation for future research.

show abstract

“…This intense selection pressure against the S protein leads to the appearance of variant mutations, thus decreasing the effectiveness of vaccines based on this protein [31] , [32] , [33] , [34] . Thus, other proteins with fewer variations may be better targets for facing this virus; Mpro as well as RNA-dependent RNA polymerase (RdRp) are two of these proteins mainly focused on, in the studies [35] , which are also exposed to possible mutations. Iketani and colleagues recently examined possible mechanisms of resistance to nirmatrelvir [36] .…”

Section: Nirmatrelvir and Sars-cov-2 Variantsmentioning

confidence: 99%